Eli Lilly's next-gen obesity drug delivered major weight loss in a trial, but some patients stopped using it after losing too ...

Eli Lilly’s next-generation obesity drug led to what appears to be the most weight loss seen so far in a late-stage trial, ...

Scientists are testing whether GLP-1 drugs can help to cut cravings for cigarettes, alcohol and opioids — as well as food.

Pfizer Inc. pulled off a comeback win, beating out Danish drug giant Novo Nordisk to acquire obesity drug developer Metsera Inc. in a deal that values the biotechnology company at up to $9.1 billion.

Dec 1 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S.

The obesity drug tirzepatide, sold as Mounjaro or Zepbound, can suppress patterns of brain activity associated with food cravings, a study suggests. Researchers measured the changing electrical ...

Eli Lilly & Co. and Novo Nordisk A/S plan to start selling their popular obesity shots to employers through a new approach that would bypass traditional drug sales channels in an effort to expand ...

Weight-loss drugs are coming for a new kind of customer. “You don’t need to be obese to start a GLP-1,” reads an ad from a telehealth startup, the words scrawled in icing on a cake. Another one ...

The World Health Organization on Monday recommended GLP-1 drugs as a tool to manage obesity in adults, marking a shift in the way the U.N. agency has historically framed obesity treatment. The WHO ...

The World Health Organization issued new guidelines Monday recommending the use of GLP-1 drugs for treating obesity. In the new guidelines, the United Nations health agency made two key ...

Novo Nordisk (NVO) and Eli Lilly (LLY) are set to introduce a new approach to expand access to weight loss drugs, selling the injectables directly to employers, thereby avoiding pharma middlemen known ...

Novo Nordisk NOVO.B0.45%increase; green up pointing triangle slashed prices for its obesity drugs months before an agreement with the Trump administration mandating that it lower its GLP-1 prices ...